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Abstract The European LeukemiaNet MDS (EUMDS) reg-
istry is collecting data of myelodysplastic syndrome (MDS)
patients belonging to the IPSS low or intermediate-1 category,
newly diagnosed by local cytologists. The diagnosis of MDS
can be challenging, and some data report inter-observer vari-
ability with regard to the assessment of the MDS subtype. In
order to ensure that correct diagnoses were made by the par-
ticipating centres, blood and bonemarrow slides of 10% of the
first 1000 patients were reviewed by an 11-person panel of
cytomorphologists. All slides were rated by at least 3 panel
members (median 8 panel members; range 3–9). Marrow
slides from 98 out of 105 patients were of good quality and
therefore could be rated properly according to the WHO 2001
classification, including assessment of dysplastic lineages.
The agreement between the reviewers whether the diagnosis
was MDS or non-MDS was strong with an intra-class
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correlation coefficient (ICC) of 0.85. Six cases were detected
not to fit the entry criteria of the registry, because they were
diagnosed uniformly as CMML or AML by the panel mem-
bers. The agreement by WHO 2001 classification was strong
as well (ICC = 0.83). The concordance of the assessment of
dysplastic lineages was substantial for megakaryopoiesis and
myelopoiesis and moderate for erythropoiesis. Our data show
that in general, the inter-observer agreement was high and a
very low percentage of misdiagnosed cases had been entered
into the EUMDS registry. Further studies including
histomorphology are warranted.
Keywords Myelodysplastic syndromes (MDS) .
Diagnostics . Cytomorphology review . Inter-observer
variability
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous
group of clonal diseases, characterized by cytopenias and dys-
plastic features in blood and bone marrow. Due to the hetero-
geneity of clinical presentation, degree of dysplastic features
and a considerable list of differential diagnosis, the diagnosis
of MDS is often a challenge, particularly in lower-risk MDS.
The diagnosis of MDS is primarily based on cytomorphologic
and histopathologic assessment of dysplasia, but cytogenetic
evaluation is crucial for the classification and to determine the
risk assessment using the revised International Prognostic
Scoring System (IPSS-R) score [1]. Flow cytometry and mo-
lecular analysis provide additional valuable information to
refine the diagnosis and prognosis of MDS, but the clinical
and therapeutic impact of these methods is under investigation
[2, 3]. To make a correct diagnosis of MDS, good
cytomorphologic experience and adequate clinical informa-
tion are required, including concomitant medication, concur-
rent infections and comorbidity, and other possible causes of
cytopenia or dysplastic features. Therefore, a multidisciplin-
ary approach is often required to make the definite diagnosis
of MDS and to exclude the possibility of other disorders mim-
icking MDS [4, 5].
In the prospective European LeukemiaNet MDS
(EUMDS) registry, patients with a newly diagnosed MDS
belonging to the low or intermediate-1 IPSS risk group are
included, within 100 days of making the definite diagnosis
of MDS [6]. Patients with higher-risk MDS or therapy-
related MDS are excluded. National and local ethics commit-
tees have approved the study, and all patients provided written
informed consent for inclusion in the registry. The first 1000
patients were diagnosed with MDS between December 2007
and December 2010, and therefore, the diagnosis was based
on theWorld Health Organization (WHO) 2001 classification,
without central revision of diagnosis. Since a correct MDS
diagnosis and classification are crucial in the EUMDS registry
and may be difficult in the lower-risk group of MDS, a mor-
phology sub-study was performed by reviewing 100 random-
ly se lec ted cases by a panel group of 11 MDS
cytomorphologists from 9 different countries. The
cytomorphology sub-study was primarily aimed at a valida-
tion and reproducibility of theWHO 2001 criteria for MDS by
an international panel and at the validation of original
cytomorphologic accuracy and correct diagnostic inclusion
into the registry. The aims of the study were (i) quality assess-
ment of cytomorphologic diagnoses in the EUMDS registry
and (ii) assessment of inter-observer variability in the review
panel regarding diagnosis and degree of dysplasia.
Design and methods
The cytomorphology review was performed by a panel com-
prising 11 morphologists during a 3-day meeting at the
Heinrich Heine University medical Centre in Düsseldorf,
Germany. The aimwas to review the original diagnosis at time
of inclusion in 10% of the patients in the EUMDS registry,
with five additional cases to replace inadequate material (only
bone marrow trephine biopsy or slides with poor quality un-
able to examine).
Selection of cases
A total of 105 cases, representing all participating countries,
were randomly selected by the Epidemiology and Cancer
Statistics Group (ECSG) of the University of York who man-
ages the Web-based EUMDS database. The distribution of the
selected samples was dependent on the number of included
patients in each country. The anonymization of the slides was
done in Nijmegen at the Trial Office Haematology (TOH) of
the Department of Haematology of the Radboud university
medical centre (Radboudumc) before transporting the slides
to Düsseldorf. The demographic, hematologic and prognostic
characteristics of the subjects included in the morphology
study were generally representative of the subjects included
in the registry at the time of sampling [6].
Clinical and haematologic characteristics
The review panel was provided with the following clinical and
haematological characteristics of the patients under review: ID
number (anonymous), date of diagnosis, haemoglobin (Hb),
white blood cells (WBC), platelets, absolute neutrophil count
(ANC), monocytes and IPSS cytogenetics category (good or
intermediate-1 risk, but not information on del(5q)) at diagno-
sis. No original morphology report or previous diagnosis was
provided to any of the panel members.
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Handling of slides
A minimum of 1 stained or unstained bone marrow slide, in
most cases 1 bone marrow iron staining and 1 blood film, had
been sent to the TOH in Nijmegen. All slides had to be from
the date of diagnosis, preferably the identical slides on which
the original diagnosis was made. Twenty unstained slides
were stained at the Radboudumc using the May-Grünwald-
Giemsa stain. The number of available iron stained slides was
restricted to 45 patients, and in 11 patients, the percentage of
ring sideroblasts were reported to be >14 by the centres. For
these 11 patients, the original iron staining was accepted by
the expert panel.
Morphology review session
The 11 panel members reviewed the slides independently
from each other during three consecutive days at the
University of Düsseldorf. Each panel member used a separate
Zeiss Axiostar Plus Transmitted-Light Microscope, provided
by Zeiss, Germany. The percentage of blasts in blood and
marrow were counted on the basis of 300 nucleated cells pre-
cisely by at least 3 experts during the review procedure; the
other panel members estimated the blast count divided in cat-
egories (<5%, 5–9% or ≥10% blasts). The degree of dysplasia
in all cell lines was scored semi-quantitatively by each review-
er, divided into three categories (absent: <10% dysplastic
cells, mild or obvious dysplasia). All slides were reviewed
by at least three individual panel members. Following individ-
ual slide review, the full panel met to consider characteristics
and diagnostic problems of specific cases. Diagnoses were
made according to the WHO classifications of 2001 [7, 8].
Definition of the review diagnosis:
1. WHO 2001 Definite diagnosis: MDS diagnosis of each
panel member based on consensus blast count done by the
whole group of that specific case and scored dysplasia in
the erythropoiesis, myelopoiesis and megakaryopoiesis.
2. WHO 2001 Expert diagnosis: MDS diagnosis of each
panel member based on individual blast count (counted
or estimated) and MDS diagnosis in conclusion.
Statistical analysis
WHO 2001 diagnoses recorded by the panel members were
categorized into the following groups:
1. Refractory anaemia (RA) and refractory anaemia with
ringed sideroblasts (RARS),
2. Refractory cytopenia with multilineage dysplasia
(RCMD) and refractory cytopenia with multilineage dys-
plasia and ringed sideroblasts (RCMD-RS),
3. Refractory anaemia with excess blasts-1 (RAEB-1),
4. Refractory anaemia with excess blasts-2/acute myeloid
leukaemia (RAEB-2/AML)
5. 5q-syndrome
6. Chronic myelomonocytic leukaemia (CMML)
7. Possible MDS (not definite MDS diagnosis)
All analyses were undertaken in Stata version 14; agree-
ment between the 11 raters was measured using the intra-class
correlation coefficient (ICC) calculated using the icc23 com-
mand [9]. The average ICC for the reliability of different re-
viewers was reported; ICC can range from 0 to 1, where 1
represents perfect agreement; agreement can be interpreted
using the following categories proposed by Landis and
Koch: <0 poor, 0.01–0.20 slight, 0.21–0.40 fair, 0.41–0.60
moderate, 0.61–0.80 substantial and 0.81–1.00 as almost per-
fect agreement [10].
Results
Median age of the randomly selected patients at diagnosis was
72 years (range 21 to 95), there was a male predominance
(67%) and the most common diagnosis recorded was
RCMD (Table 1). In total, 774 slides were reviewed by the
11 raters, 45 slides (5.8%) were excluded from subsequent
analyses as the panel members were unable to review the
diagnosis due to the poor quality of the slide. One case was
removed as only two panel members had reviewed it.
Accordingly, in total, 98 cases were included in the review,
and, on average, each case was reviewed by eight different
panel members (range 3–9). In total, 727 diagnoses were
made by the panel members.
Concordance of MDS diagnoses
In a first step, the concordance with regard to the diagnosis of
an MDS versus non-MDS was analysed. Differences were
seen by reviewer in the proportion of cases reviewed, as can
be seen in Fig. 1; in addition, this figure demonstrates the
difference in the proportion of diagnoses queried to whether
or not the case had MDS (‘possible MDS’). Overall, 8% of
cases were classified as ‘possible’MDS, but reviewer 11 clas-
sified 27% of cases to this category, all of them were rated to
have <5%medullary blasts. For the majority of slides, a MDS
diagnosis was made (88%). Eleven slides were classified as
RAEB-2 or AML, 23 as CMML and 58 as possible MDS
cases. In Table 2, the number of possible MDS is not included
itself, but can be deducted from the numbers of different MDS
diagnosis by panel review and the total number of slides
(Table 2). Agreement between the reviewers whether the di-
agnosis was MDS or non-MDS was strong ICC = 0.85 (95%
confidence intervals (95%CI): 0.80–0.89).
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Concordance of WHO 2001 diagnoses
In the next step, the concordance of WHO 2001 subtypes was
analysed (Fig. 2). The agreement by WHO 2001 diagnoses
was almost identical; ICC = 0.83 (95%CI: 0.77–0.87). Table 2
describes the review panel diagnoses made versus the original
diagnosis recorded in the registry. We also assessed the med-
ullary blast categories by separating patients with <5%, 5–9%,
10–19% and >20% medullary blasts. A total of 88.4% of the
slides were scored as less than 5% medullary blasts, 10% as
RAEB-1, 0.9% as RAEB-2 and 0.5% as AML. The inter-
observer variability for this categorization was very low, as
only 6% of the slides were described differently by at least one
panel member.
Concordance of assessment of dysplasia
In addition, we analysed the concordance of the assessment of
dysplastic lineages (Table 3). The number of slides in which
either dyserythropoiesis (9.9%), dysmyelopoiesis (7.5%) or
dysmegakaryopoiesis (21.1%) could not be assessed properly
was relatively high, especially in the slides that were described
as possible MDS. Looking at the dysplastic lineages in the
different WHO types, it became obvious that in the unilineage
dysplastic types (RA/RARS), in 23.8 and 9.4% of the slides,
dysmyelopoiesis and dysmegakaryopoiesis were described,
respectively, whereas in the RCMD/RCMD-RS group, these
numbers were higher (49.5 and 54.9%). Dyserythropoiesis
was described to be less frequent in the RA/RARS and 5q-
syndrome groups as compared to the RCMD/RCMD-RS
group . As expec ted , the h ighes t pe rcentage of
dysmegakaryopoiesis was described in the 5q-syndrome
group. In cases that were labelled ‘possible MDS’, the per-
centage of dyserythropoiesis was lower compared to definite
MDS cases, and only a very small proportion showed
dysmyelopoiesis with none showing dysmegakaryopoiesis.
The agreement of the reviewers with regard to the assessment
of dysmegakaryopoiesis (0.60; 95% CI: 0.48, 0.71) and
dysmyelopoiesis (0.72; 95% CI: 0.64, 0.80) was substantial
and for dyserythropoiesis was moderate, close to substantial
(0.591; 95% CI: 0.464, 0.699).
Comparison of original diagnoses and panel diagnoses
In a last step, we compared the diagnoses made by the centres
that entered the patients into the lower-risk EUMDS registry.
We identified 6 cases (6.1%) that did not fulfil the entry
criteria. Four patients were described to have CMML by all
Table 1 Patient characteristics at registration to the registry
N (%)
Total 98 (100)
Age at diagnosis (years), median (range) 72.0 (21.0–95.0)
Sex
Males 66 (67.3)
Females 32 (32.7)
Country
Austria 2 (2.0)
Czech Republic 7 (7.1)
Denmark 3 (3.1)
France 30 (30.6)
Germany 7 (7.1)
Greece 11 (11.2)
Italy 2 (2.0)
Netherlands 8 (8.2)
Poland 2 (2.0)
Romania 4 (4.1)
Sweden 8 (8.2)
United Kingdom 14 (14.3)
Haemoglobin (g/dL), mean (SD) 10.5 (2.0)
WBC (109/L) mean (SD) 4.9 (2.4)
Absolute neutrophil count (109/L) mean (SD) 3.0 (2.0)
Platelets (109/l) mean (SD) 183 (121)
WHO diagnosis provided at time of entry into the registry
RA 17 (17.3)
RARS 20 (20.4)
RCMD 40 (40.8)
RCMD-RS 3 (3.1)
RAEB-1 14 (14.3)
5q-syndrome 4 (4.1)
IPSS Score
Low 344 (47.3)
Intermediate-1 345 (47.5)
Not known 38 (5.2)
RA refractory anaemia, RARS refractory anaemiawith ringed sideroblasts,
RCMD Refractory cytopenia with multilineage dysplasia, RCMD-RS re-
fractory cytopenia with multilineage dysplasia and ringed sideroblasts,
RAEB-1 refractory anaemia with excess blasts-1, 5q-syndrome
Fig. 1 Proportion of cases reviewed by each panel member and expert
diagnoses made
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panel members who assessed the slides of blood and marrow
with 100% agreement. Both patients were originally entered
into the registry as RA and RAEB-1. Two patients were diag-
nosed as RAEB-2 or AML by the panel members with 100%
agreement. These patients were entered into the registry as
RCMD and RAEB-1.
Discussion
Diagnosis of MDS is still based primarily on cytomorphology
of blood and marrow, accompanied by histomorphology, cy-
togenetics, molecular findings and flow cytometry. The
EUMDS registry is collecting data of newly diagnosed
lower-risk MDS patients. Eligibility for entry into the registry
is based on the local assessment of cytomorphology at the
participating centres in 14 different countries and 118 sites.
In order to assess the quality and accuracy of the MDS diag-
noses in the registry, we organized a working group reviewing
10% of the first 1000 patients that were included into the
registry. In our cytomorphologic review of 100 newly diag-
nosed lower-risk MDS patients, we could clearly demonstrate
a high accuracy of the original diagnoses at entry into the
registry and a high inter-observer concordance of the panel
members with regard to diagnosis of MDS and assessment
of the lineage involvement of dysplasia.
An important prerequisite for cytology is satisfactory
quality-stained slides, in our case well-prepared blood and
marrow films and ‘bone marrow aspirate squash’ slides with-
out many preparation artefacts. Only 6% of the slides were of
poor quality and could not be assessed properly, whereas 94%
could be validated. Cytomorphology inMDS can be challeng-
ing, even for experienced morphologists, and sometimes a
definite diagnosis is not possible or only based on genetic
findings [11]. Minimal diagnostic criteria for the diagnosis
of an MDS cannot be based on morphology only, as no single
sign of dysplasia is MDS specific [12]. The slides that were
evaluated during our microscope session were blinded, and
the panel member did not have information on the clinical
course of the patients and were not biased in their judgement.
We assembled a very heterogeneous panel of cytologists in
terms of the morphological experience of the members, and
therefore we were prepared to be faced with discrepancies in
the assessment of the diagnosis. Surprisingly, most disagree-
ments were not significant. First of all, a small number of
slides were detected as CMML and RAEB-2 and AML cases.
This task was the easiest for the panel members as there was
no disagreement. As a result, only 6% of the patients who
entered into the registry were misdiagnosed by the centres.
This confirms that the data quality of the registry is high and
that subsequent analyses based on diagnosis by the local
cytomorphologists are likely to be valid. The assessment of
medullary blast counts was also extremely uniform, as only
6% of the cases were differently categorized (<5% blasts ver-
sus 5–9% blasts).
Table 2 Expert diagnoses
(review panel) by original
diagnoses by local cytologists
(clinical)
Original diagnosis by local cytologists
Review panel
diagnosis
RA/RARS
(n = 37
pts)
RCMD/RCMD-RS
(43 pts)
RAEB-1
(n = 14
pts)
5q-syndrome
(n = 4 pts)
Total
(n = 98
pts)
Total 265 (100.0) 326 (100.0) 106 (100.0) 30 (100.0) 727
(100.0)
RA/RARS 50 (18.9) 36 (11.0) 4 (3.8) - 90 (12.4)
RCMD/RCMD-RS 155 (58.5) 232 (71.2) 51 (48.1) - 438 (60.2)
RAEB-1 21 (7.9) 27 (8.3) 21 (19.8) - 69 (9.5)
RAEB-2/AML - 4 (1.2) 7 (6.6) - 11 (1.5)
5q-syndrome - - 8 (7.5) 30 (100.0) 38 (5.2)
CMML 9 (3.4) - 14 (13.2) - 23 (3.2)
RA refractory anaemia, RARS refractory anaemia with ringed sideroblasts, RCMD refractory cytopenia with
multilineage dysplasia, RCMD-RS refractory cytopenia with multilineage dysplasia and ringed sideroblast,
RAEB-1 refractory anaemia with excess blasts-1, RAEB-2 refractory anaemia with excess blasts, AML acute
myeloid leukaemia, 5q-syndrome, CMML chronic myelomonocytic leukaemia, pts patients
Fig. 2 Original diagnoses by local cytologists versus expert diagnoses
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The assessment of lineage involvement of dysplasia was less
concordant. Inter-observer variability with regard to description
of dysplasia was reported by several groups [13–15]. Our data
show that our Panel team had substantial agreement on the as-
sessment of dysmyelopoiesis and dysmegakaryopoiesis, whereas
the assessment of dyserythropoiesis was less concordant. This
finding is plausible, as some signs of dysplasia in myelo- and
megakaryopoiesis are more specific for myeloid malignancies
like micromegakaryocytes, mononuclear megakaryocytes,
pseudo-pelger cells and degranulated myeloid precursors.
These signs of dysplasia are usually not described in the marrow
with reactive changes due to inflammation, toxic effects and
others [12]. Morphological erythroid dysplasia can be evident
in benign disorders like hemolysis, megaloblastic anemias and
others. As a result, the panel members differed moderately in the
categorization of uni- versus multilineage dysplasia. There is
growing evidence that flow cytometry with regard to properly
described dysplasia of erythropoiesis can be utilized if performed
in a sophisticated way [3, 16, 17]. The separation of lower-risk
MDS cases, namely distinguishing uni- and multilineage dyspla-
sia, ring sideroblastic phenotype, and deletion of chromosome 5
is of great prognostic value, as shown by different groups
[18–21]. As our data show, knowledge of cytomorphology is
necessary to properly describe dysplasia and to use the classifi-
cation systems accordingly. Therefore, skills in cytomorphology
are still mandatory in centres where patients with MDS are diag-
nosed and treated accordingly [22, 23].
The WHO 2001 proposals for the classification of MDS
took into account the separation of uni- and multilineage dys-
plasia within the non-blastic MDS cases with ring
sideroblasts. This feature was omitted by the WHO 2008
[24] proposals but was reintroduced in the WHO 2016 classi-
fication [21]. As a result, our data generally reflect the WHO
2016 classification with the exception of minor changes of the
definition of MDS del(5q) and MDS unclassified and the in-
troduction of SF3B1 mutations as classifying elements.
The slides that were evaluated during our microscope ses-
sions were blinded and the panel members did not have infor-
mation on the clinical course of the disease. The only bias was
the information that slides have been diagnosed as lower-risk
MDS by the local cytologists.
Limitations of the project were some missing iron stains,
not primarily affecting the morphological results with regard
to eligibility of the patients into the registry. An even better
assessment of morphology could have been reached by adding
histomorphology for all cases. Although the impact of
histomorphology in lower-risk MDS is limited as compared
with cytomorphology, it can be helpful in cases with poor
cytologic material and can help to properly assess the cellu-
larity and fibrosis [25]. Therefore, another panel review, in-
cluding histopathologists, could be of added value.
In summary, there was a high inter-observer agreement
after the elimination of poor quality slides within our very
heterogeneous panel of 11 morphologists. As a result, the
inclusion of the patients into the EUMDS registry could be
shown to be correct in the vast majority of the patients. The 6
patients originally not diagnosed correctly by the local cytol-
ogists have not been withdrawn from the registry. The registry
is assessing patients who were diagnosed in the real world as
lower-risk MDS and managed as such. Therefore, a central
Table 3 Proportion with abnormalities by the expert diagnosis
RA/RARS RCMD/RCMD-RS RAEB-1 RAEB-2/AML 5q-syndrome CMML Possible MDS Total
Total number (%) 90 (100) 438 (100) 69 (100) 11 (100) 38 (100) 23 (100) 58 (100) 727 (100)
Dyserythropoiesis
No 19 (25.7) 14 (3.3) 10 (16.7) - 3 (9.1) 3 (13.6) 13 (41.9) 62 (9.5)
Mild 29 (39.2) 159 (37.2) 26 (43.3) 4 (50.0) 17 (51.5) 11 (50.0) 16 (51.6) 262 (40.0)
Obvious 26 (35.1) 254 (59.5) 24 (40.0) 4 (50.0) 13 (39.4) 8 (36.4) 2 (6.5) 331 (50.5)
Not known 16 11 9 3 5 1 27 72
Dysgranulopoiesis
No 53 (66.3) 43 (10.1) 6 (9.2) - 9 (25.7) 5 (22.7) 22 (62.9) 138 (20.5)
Mild 8 (10.0) 172 (40.4) 20 (30.8) 4 (44.4) 13 (37.1) 7 (31.8) 12 (34.3) 236 (35.1)
Obvious 19 (23.8) 211 (49.5) 39 (60.0) 5 (55.6) 13 (37.1) 10 (45.5) 1 (2.9) 298 (44.3)
Not known 10 12 4 2 3 1 23 55
Dysmegakaryopoiesis
No 42 (79.2) 45 (12.2) 14 (24.6) - 1 (2.7) 7 (33.3) 20 (71.4) 129 (22.5)
Mild 6 (11.3) 122 (33.0) 19 (33.3) 3 (42.9) 5 (13.5) 5 (23.8) 8 (28.6) 168 (29.3)
Obvious 5 (9.4) 203 (54.9) 24 (42.1) 4 (57.1) 31 (83.8) 9 (42.9) - 276 (48.2)
Not known 37 68 12 4 1 2 30 154
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morphology review is not mandatory for this particular
registry.
Acknowledgements The authors and members of the steering commit-
tee of the EUMDS registry would like to thank Judith Neukirchen at the
Heinrich Heine University medical center in Düsseldorf, Germany, for
hosting the 3-day cytomorphology review meeting, the research group at
Radboud university medical center, Nijmegen, especially Margot Reker,
for the administrative and logistical support in, e.g. transportation and
anonymization of the slides, all local investigators and operational team
members for their contribution to the registry.
Compliance with ethical standard National and local ethics commit-
tees have approved the study, and all patients provided written informed
consent for inclusion in the registry.
Conflict of interest The authors declare that they have no conflict of
interest.
Financial support The work of the EUMDS Registry for low and
intermediate-1 MDS is supported by an educational grant from Novartis
Oncology Europe.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Germing U, Kobbe G, Haas R, Gattermann N (2013)
Myelodysplastic syndromes: diagnosis, prognosis, and treatment.
Dtsch Arztebl Int 110(46):783–790. doi:10.3238/arztebl.2013.
0783
2. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G,
Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H,
Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J,
Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M,
Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M,
Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T,
van de Loosdrecht AA, Germing U, Haase D (2012) Revised inter-
national prognostic scoring system for myelodysplastic syndromes.
Blood 120(12):2454–2465
3. Westers TM, Cremers EM, Oelschlaegel U, Johansson U,
Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE,
Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van
der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra
K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della
Porta MG, Kern W, van de Loosdrecht AA, IMDSFlow Working
Group (2017) Immunophenotypic analysis of erythroid dysplasia in
myelodysplastic syndromes. A report from the IMDSFlowworking
group. Haematologica 102(2):308–319. doi:10.3324/haematol.
2016.147835
4. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma
DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-
Manero G, Ebert BL (2012) Validation of a prognostic model and
the impact of mutations in patients with lower-risk myelodysplastic
syndromes. J Clin Oncol 30(27):3376–3382. doi:10.1200/JCO.
2011.40.7379
5. Malcovati L, Hellstrom-Lindberg E, Bowen D, Adès L, Cermak J,
Del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing
U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF,
Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de
Loosdrecht AA, de Witte T, Cazzola M, Net EL (2013) Diagnosis
and treatment of primary myelodysplastic syndromes in adults: rec-
ommendations from the European LeukemiaNet. Blood 122(17):
2943–2964. doi:10.1182/blood-2013-03-492884
6. de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P,
Symeonidis A, Sanz G, Hellström-Lindberg E, Cermák J, Germing
U, Stauder R, Georgescu O, MacKenzie M, Malcovati L, Holm
MS, Almeida AM, Mądry K, Slama B, Guerci-Bresler A, Sanhes
L, Beyne-Rauzy O, Luño E, Bowen D, de Witte T (2015)
Validation of the revised international prognostic scoring system
(IPSS-R) in patients with lower-risk myelodysplastic syndromes:
a report from the prospective European LeukaemiaNet MDS
(EUMDS) registry. Br J Haematol 170(3):372–383. doi:10.1111/
bjh.13450
7. Bennett JM (2000) World Health Organization classification of the
acute leukemias and myelodysplastic syndrome. Int J Hematol
72(2):131–133
8. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D,
Varidman JW, Harris NL (2001) Myelodysplastic syndromes. In:
Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Pathology and
genetics of Tumours of Haematopoietic and lymphoid tissues.
IARC press, Lyon, pp 61–74
9. Shrout PE, FLeiss JL (1979) Intraclass correlation: uses in assessing
rater reliability. Psychol Bull 86(2):420–428
10. Landis JR, Koch GG (1977) The measurement of observer agree-
ment for categorical data. Biometrics 33(1):159–174
11. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U,
Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, Loken
M, van de Loosdrecht A, Ogata K, Orfao A, Pfeilstöcker M, Rüter
B, Sperr WR, Stauder R, Wells DA (2007) Definitions and stan-
dards in the diagnosis and treatment of the myelodysplastic syn-
dromes: consensus statements and report from a working confer-
ence. Leuk Res 31(6):727–736
12. Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N,
Starke C, Aul C (2012) Evaluation of dysplasia through detailed
cytomorphology in 3156 patients from the Dusseldorf registry on
myelodysplastic syndromes. Leuk Res 36(6):727–734. doi:10.
1016/j.leukres.2012.02.014
13. Font P, Loscertales J, Soto C, Ricard P, Novas CM, Martín-Clavero
E, López-Rubio M, Garcia-Alonso L, Callejas M, Bermejo A,
Benavente C, Ballesteros M, Cedena T, Calbacho M, Urbina R,
Villarrubia J, Gil S, Bellón JM, Diez-Martin JL, Villegas A
(2015) Interobserver variance in myelodysplastic syndromes with
less than 5% bone marrow blasts: unilineage vs. multilineage dys-
plasia and reproducibility of the threshold of 2% blasts. Ann
Hematol 94(4):565–573. doi:10.1007/s00277-014-2252-4
14. Font P, Loscertales J, Benavente C, Bermejo A, Callejas M, Garcia-
Alonso L, Garcia-Marcilla A, Gil S, Lopez-Rubio M, Martin E,
Muñoz C, Ricard P, Soto C, Balsalobre P, Villegas A (2013) Inter-
observer variance with the diagnosis of myelodysplastic syndromes
(MDS) following the 2008 WHO classification. Ann Hematol
92(1):19–24. doi:10.1007/s00277-012-1565-4
15. Ramos F, Fernandez-Ferrero S (2013) Inter-observer agreement in
myelodysplastic syndromes. Haematologica 98(7):e77. doi:10.
3324/haematol.2013.91231
16. Cremers EM, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA,
Chitu DA, van der Velden VH, TeMarvelde JG, Klein SK, Muus P,
Vellenga E, de Greef GE, Legdeur MC, Wijermans PW, Stevens-
Kroef MJ, Silva-Coelho PD, Jansen JH, Ossenkoppele GJ, van de
Loosdrecht AA, A study on behalf of the HOVON89 study group
Ann Hematol (2017) 96:1105–1112 1111
(2017) Implementation of erythroid lineage analysis by flow cytom-
etry in diagnostic models for myelodysplastic syndromes.
Haematologica 102(2):320–326. doi:10.3324/haematol.2016.
147843
17. Cremers EM, Westers TM, Alhan C, Cali C, Wondergem MJ,
Poddighe PJ, Ossenkoppele GJ, van de Loosdrecht AA (2016)
Multiparameter flow cytometry is instrumental to distinguish
myelodysplastic syndromes from non-neoplastic cytopenias. Eur J
Cancer 54:49–56. doi:10.1016/j.ejca.2015.11.013
18. Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000)
Validation of the WHO proposals for a new classification of prima-
ry myelodysplastic syndromes: a retrospective analysis of 1600
patients. Leuk Res 24(12):983–992
19. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R,
Hellström-Lindberg E (2004) The WHO classification of MDS
does make a difference. Blood 103(9):3265–3270
20. Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B,
Giagounidis A, Aul C, Gattermann N, Haas R (2006) Prospective
validation of the WHO proposals for the classification of
myelodysplastic syndromes. Haematologica 91(12):1596–1604
21. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau
MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016
revision to the World Health Organization classification of myeloid
neoplasms and acute leukemia. Blood 127(20):2391–2405. doi:10.
1182/blood-2016-03-643544
22. Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning
R, Cazzola M, Fenaux P, Germing U, Hellström-Lindberg E, Jinnai
I, Manabe A, Matsuda A, Niemeyer CM, Sanz G, Tomonaga M,
Vallespi T, Yoshimi A, International Working Group on
Morphology of Myelodysplastic Syndrome (2008) Diagnosis and
classification of myelodysplastic syndrome: international working
group on morphology of myelodysplastic syndrome (IWGM-
MDS) consensus proposals for the definition and enumeration of
myeloblasts and ring sideroblasts. Haematologica 93(11):1712–
1717. doi:10.3324/haematol.13405
23. Bennett JM (2013) Morphological classification of the
myelodysplastic syndromes: how much more education of diag-
nosticians is necessary? Haematologica 98(4):490–491. doi:10.
3324/haematol.2013.084418
24. Brunning RD, Orazi A, Germing U, LeBeau MM, Porwit A,
Baumann I, Vardiman JW, Hellstrom-Lindberg E (2008)
Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow
SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J,
Vardiman JW (eds) WHO classification of Tumours of
Haematopoietic and lymphoid tissues, 4th edn. IARC press, Lyon
25. Schemenau J, Baldus S, Anlauf M, Reinecke P, Braunstein S, Blum
S, Nachtkamp K, Neukirchen J, Strup C, Aul C, Haas R,
Gattermann N, Germing U (2015) Cellularity, characteristics of
hematopoietic parameters and prognosis in myelodysplastic syn-
dromes. Eur J Haematol 95(3):181–189. doi:10.1111/ejh.12512
1112 Ann Hematol (2017) 96:1105–1112
